Skip to main content

Table 2 Clinicopathologic correlation of tumour microenvironment immune types, CD8 expression, and PD-L1 expression

From: Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma

ParametersTumour microenvironment immune type (%)CD8 expression (%)PD-L1 expression (%)
 Type I(PDL1+/CD8H)Type IV(PD-L1−/CD8H)Type III(PD-L1+/
CD8L)
Type II
(PD-L1−/CD8L)
PLowHighPNeg.Pos.P
AgeLess than 67 yrs36 (17.4)36 (17.4)35 (16.9)100 (48.3)0.366135 (65.2)72 (34.8)0.575136 (65.4)72 (35.6)0.303
More than 67 yrs54 (19.9)47 (17.3)52 (19.2)118 (43.5) 170 (62.7)101 (37.3) 166 (60.8)107 (39.2) 
SexMale58 (20.3)57 (19.9)46 (16.1)125 (43.7)0.094171 (59.8)115 (40.2)0.026*182 (63.2)106 (36.8)0.821
Female32 (16.7)26 (13.5)41 (21.4)93 (48.4) 134 (69.8)58 (30.2) 120 (62.2)73 (37.8) 
SizeLess than 4.9 cm50 (20.0)48 (19.2)43 (17.2)109(43.6)0.227152 (60.8)98 (39.2)0.15 l2157 (62.5)94 (37.5)0.911
More than 4.9 cm40 (17.5)35 (15.4)44 (19.3)109 (47.8) 153 (67.1)75 (32.9) 145 (63.0)85 (37.0) 
LocationAscending26 (24.3)18 (16.8)22 (20.6)41 (38.3)0.91263 (58.9)44 (41.1)0.84959 (54.6)49 (45.4)0.517
Transverse to
sigmoid
34 (14.2)41 (17.2)42 (17.6)122 (51.0) 164 (68.6)75 (31.4) 164 (68.3)76 (31.7) 
Rectum27 (23.1)22 (18.8)20 (17.1)48 (41.0) 68 (58.1)49 (41.9) 70 (59.3)48 (40.7) 
Histologic typeIntestinal type89 (18.9)83 (17.7)87 (18.5)211 (44.9)0.080298 (63.4)172 (36.6)0.160295 (62.4)178 (37.6)0.145
Mucinous type1 (12.5)0 (0.0)0 (0.0)7 (87.5) 7 (87.5)1 (12.5) 7 (87.5)1 (12.5) 
DifferentiationWell9 (17.6)14 (27.5)8 (15.7)20 (39.2)0.79528 (54.9)23 (45.1)0.45834 (65.4)18 (34.600.483
Moderately75 (18.7)66 (16.5)76 (19.0)184 (45.7) 260 (64.8)141 (35.2) 251 (62.3)152 (37.7) 
Poorly5 (27.8)3 (16.7)3 (16.7)7 (38.9) 10 (55.6)8 (44.4) 10 (55.6)8 (44.4) 
Lymphovascular invasionAbsence65 (20.4)47 (14.8)58 (18.2)148 (46.5)0.955206 (64.8)112 (35.2)0.503196 (61.1)125 (38.9)0.211
Presence21 (14.7)34 (23.8)26 (18.2)62 (43.4) 88 (61.5)55 (38.5) 96 (67.1)47 (32.9) 
Perineural invasionAbsence58 (19.7)43 (14.6)59 (20.0)135 (45.8)0.650194 (65.8)101 (34.2)0.808178 (60.3)117 (39.7)0.116
Presence7 (14.0)11 (22.0)7 (14.0)25 (50.0) 32 (64.0)18 (36.0) 36 (72.0)14 (28.0) 
pT categorypT1–226 (32.9)17 (21.5)15 (19.0)21(26.6)<  0.001*36 (45.6)43 (54.4)0.001*178 (60.3)117 (39.7)0.001*
pT358 (16.8)56 (16.2)65 (18.8)166(48.0) 231 (67.0)114 (33.0) 36 (72.0)14 (28.0) 
pT46 (11.1)10 (18.5)7 (13.0)31 (57.4) 38 (70.4)16 (29.6) 178 (60.3)117 (39.7) 
Lymph node metastasisAbsence68 (25.3)43 (16.0)47 (17.5)111 (41.3)0.001*158 (58.7)111(41.3)0.009*154 (56.8)117 (43.2)0.002*
Presence22 (10.5)40 (19.1)40 (19.1)107 (51.2) 147 (70.3)62 (29.3) 148 (70.5)62 (29.5) 
StageI24 (37.5)11 (17.2)11 (17.2)18 (28.1)0.001*29 (45.3)35 (54.7)0.006*29 (45.3)35 (54.7)0.003*
II41 (20.5)30 (15.0)34 (17.0)95 (47.5) 129 (64.5)71 (35.5) 125 (61.9)77 (38.1) 
III21 (10.9)38 (19.6)38 (19.8)95(19.5) 133 (69.3)59(30.7) 134 (69.4)59 (30.6) 
IV4 (18.2)4 (18.2)4 (18.2)10 (45.5) 14 (63.6)8 (36.4) 14 (63.6)8 (36.4) 
Deficient mismatch repairAbsence76 (17.3)76 (17.3)81 (18.5)206 (46.9)0.006*287 (65.4)152 (34.6)0.017*283 (64.2)158 (35.8)0.037*
Presence14 (35.9)7 (17.9)6 (15.4)12 (30.8) 18 (46.2)21 (53.8) 19 (47.5)21 (52.5) 
Neoadjuvant chemoradiotherapyAbsent88 (18.2)77 (16.5)86 (18.5)215 (46.1)0.025*301 (64.6)165 (35.4)0.026*293 (62.5)176 (37.5)0.375
Present2 (16.7)6 (50.0)1 (8.3)3 (25.0) 4 (33.3)8 (66.7) 9 (75.0)3 (25.0) 
Local recurrenceAbsence67 (22.3)51 (17.0)52 17.3)130 (43.3)0.031*182 (60.7)118 (39.3)0.064181 (59.9)121 (40.1)0.093
Presence23 (12.9)32 (18.0)35 (19.7)88 (49.4) 123 (69.1)55 (30.9) 121 (67.6)58 (32.4) 
Disease-specific deathAlive69 (24.0)49 (17.1)48 (16.7)121 (42.2)0.002*169 (58.9)118 (41.1)0.006*170 (58.8)119 (41.2)0.027*
Dead21 (11.0)34 (17.8)39 (20.4)97 (50.8) 136 (71.2)55 (28.8) 132 (68.8)60 (31.3) 
  1. Cases without clinical information or for which data are not assessable due to cautery artifact, fragmentation, or incorrect orientation of tumour tissues are excluded from statistical analyses